PRMT1 and hepatocellular carcinoma: Specifically, in a subgroup of individuals with diminished liver Protein arginine methyltransferase 1 (PRMT1) and high iNOS activity levels, the findings provided in this research show that selective iNOS inhibition is a potential approach for treating alcoholic liver disease ALD and alcohol-associated HCC.